Dose (adults): The recommended dose for Moxifloxacin is 400mg once daily (1 film-coated tablet) for the previously mentioned indications and should not be exceeded.
Duration of treatment: The duration of treatment should be determined by the severity of the indication or clinical response.
The following general recommendations for the treatment of upper and lower respiratory tract infections are made: Bronchitis: acute exacerbation of chronic bronchitis, 5 days.
Pneumonia: community acquired pneumonia, 10 days.
Sinusitis: acute sinusitis, 7 days.
Mild to moderately severe inflammatory pelvic diseases: 14 days.
Complicated skin and skin structure infections total treatment duration for sequential therapy (intravenous followed by oral therapy): 7 - 21 days.
Complicated intraabdominal infections total treatment duration for sequential therapy (intravenous followed by oral therapy): 5 - 14 days.
The recommended duration of treatment for the indication being treated should not be exceeded.
Geriatric patients: No adjustment of dosage is required in the elderly.
Pediatric Patients: The efficacy of Moxifloxacin in children and adolescents has not been established. No recommendation on posology can be made. The safety of Moxifloxacin in children below the age of 6 years has not been established.
Ethnic differences: No adjustment of dosage is required in ethnic groups.
Patients with hepatic impairment: No dosage adjustment is required in patients with impaired liver function.
Patients with renal impairment: No dose adjustment is required in patients with renal impairment (including creatinine clearance < 30mL/min/1.73m2) and in patients on chronic dialysis i.e. hemodialysis and continuous ambulatory peritoneal dialysis.
Route of Administration: For oral use. The film-coated tablet should be swallowed whole with sufficient liquid/water and may be taken independent of meals.